Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes
Top Cited Papers
- 1 May 2014
- journal article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 50 (7), 1361-1369
- https://doi.org/10.1016/j.ejca.2014.01.018
Abstract
No abstract availableThis publication has 31 references indexed in Scilit:
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant DiseaseJournal of Clinical Oncology, 2013
- Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.Cancer Control, 2013
- What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?Annals of Oncology, 2012
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II StudyJournal of Clinical Oncology, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Targeted therapies for advanced non-small-cell lung cancer: Current status and future implicationsCancer Treatment Reviews, 2012
- Cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2002